XGEVA
Biological
Amgen Inc.
Total Payments
$31.2M
Transactions
13,932
Doctors
5,031
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $341,814 | 48 | 12 |
| 2023 | $780,024 | 572 | 438 |
| 2022 | $802,912 | 1,887 | 1,178 |
| 2021 | $1.7M | 2,645 | 1,667 |
| 2020 | $2.5M | 1,951 | 1,230 |
| 2019 | $7.7M | 2,235 | 1,020 |
| 2018 | $7.3M | 2,328 | 880 |
| 2017 | $10.0M | 2,266 | 669 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.6M | 1,222 | 88.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 1,143 | 6.2% |
| Consulting Fee | $850,199 | 253 | 2.7% |
| Travel and Lodging | $442,971 | 1,085 | 1.4% |
| Food and Beverage | $306,201 | 10,175 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $53,226 | 45 | 0.2% |
| Royalty or License | $6,200 | 2 | 0.0% |
| Education | $87.56 | 7 | 0.0% |
Payments by Type
Research
$27.6M
1,222 transactions
General
$3.6M
12,710 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| P3 Multiple Myeloma Frontline | Amgen Inc. | $8.4M | 2 |
| AMG 162_Denosumab 120 mg/mL High Concentration BE study | Amgen Inc. | $4.7M | 0 |
| P3 Adjuvant Breast Cancer | Amgen Inc. | $2.9M | 0 |
| GCTB LTFU Study | Amgen Inc. | $2.6M | 0 |
| A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency | Amgen Inc. | $1.3M | 0 |
| Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma | Amgen Inc. | $1.2M | 0 |
| GCTB LTFU Study. | Amgen Inc. | $842,919 | 0 |
| Giant Cell Tumor | Amgen Inc. | $820,392 | 2 |
| Denosumab for Smoldering Multiple Myeloma | Amgen Inc. | $781,459 | 0 |
| An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia | Amgen Inc. | $717,869 | 0 |
| Prevention of breast cancer by Denosumab in females carrying a BRCA1 or 2 mutation | Amgen Inc. | $712,127 | 0 |
| Phase 2 Study of Denosumab in Combination with a PD-1 Inhibitor in Subjects with Stage III/IV Melanoma | Amgen Inc. | $549,244 | 0 |
| Pre-surgical evaluation of denosumab in patients with operable invasive breast cancer | Amgen Inc. | $399,535 | 0 |
| Defining the Immunologic Impact of Denosumab in Patients with Bone Metastases | Amgen Inc. | $280,388 | 0 |
| Pilot study of denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oophorectomy | Amgen Inc. | $237,524 | 0 |
| A Phase II, single arm clinical study of denosumab effect on breast density and breast tissue biomarkers | Amgen Inc. | $164,833 | 0 |
| Denosumab treatment for prevention of skeletal disease progression in children with fibrous dysplasia | Amgen Inc. | $159,157 | 0 |
| Phase 2 Study of Denosumab in Combination with Pembrolizumab in Patients with Unresectable Stage III/IV Cutaneous Melanoma | Amgen Inc. | $148,505 | 0 |
| Ph 2 XGEVA vs SOC in NSCLC | Amgen Inc. | $131,331 | 0 |
| Phase II study of denosumab to define the role of bone related biomarkers in breast cancer bone metastasis | Amgen Inc. | $109,836 | 0 |
Top Doctors Receiving Payments for XGEVA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Moreno Valley, CA | $19,105 | 21 |
| , M.D | Medical Oncology | Boston, MA | $18,415 | 4 |
| , MD | Medical Oncology | Rapid City, SD | $18,152 | 21 |
| , M.D | Hematology | Lady Lake, FL | $17,698 | 17 |
| , M.D | Medical Oncology | Spokane, WA | $17,628 | 15 |
| , MD | Urology | West Bloomfield, MI | $16,812 | 25 |
| , MD | Internal Medicine | San Francisco, CA | $16,323 | 4 |
| , M.D | Internal Medicine | Las Vegas, NV | $16,178 | 11 |
| , MD | Hematology & Oncology | Cleveland, OH | $15,554 | 4 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $15,485 | 14 |
| , M. D | Pediatrics | San Francisco, CA | $14,399 | 8 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $14,347 | 6 |
| , M.D | Hematology & Oncology | Miami, FL | $14,047 | 19 |
| , MD | Internal Medicine | New York, NY | $13,736 | 14 |
| , MD,PHD | Specialist | Indianapolis, IN | $13,724 | 12 |
| , MD | Urology | Middleburg Heights, OH | $13,300 | 30 |
| , MD | Hematology & Oncology | Philadelphia, PA | $13,235 | 6 |
| , MD | Nephrology | Denver, CO | $13,227 | 9 |
| , MD | Medical Oncology | New York, NY | $12,558 | 2 |
| , MD | Internal Medicine | San Francisco, CA | $12,544 | 8 |
| , MD | Hematology & Oncology | Los Angeles, CA | $12,203 | 4 |
| , MD | Internal Medicine | Greenville, NC | $11,536 | 8 |
| , M.D | Internal Medicine | Columbus, OH | $11,450 | 11 |
| , M.D | Hematology & Oncology | Washington, DC | $11,426 | 10 |
| , M.D | Hematology & Oncology | Louisville, KY | $11,368 | 10 |
Ad
Manufacturing Companies
- Amgen Inc. $31.2M
Product Information
- Type Biological
- Total Payments $31.2M
- Total Doctors 5,031
- Transactions 13,932
About XGEVA
XGEVA is a biological associated with $31.2M in payments to 5,031 healthcare providers, recorded across 13,932 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $341,814 was paid across 48 transactions to 12 doctors.
The most common payment nature for XGEVA is "Unspecified" ($27.6M, 88.5% of total).
XGEVA is associated with 20 research studies, including "P3 Multiple Myeloma Frontline" ($8.4M).